同步放化疗治疗肺癌椎体转移30例临床观察

 目的 探讨同步放化疗治疗肺癌椎体转移的临床疗效及毒副反应。 方法 对30例非小细胞肺癌并椎体转移、ECOG评分0~2分的患者采用DP方案 （多西他赛75mg/m²+顺铂75mg/m²，静脉滴注，d1）全身 化疗，同步椎体局部外照射，常规分割放疗，2.0Gy/次，1次/天，5次/周，共4周，总剂量为40Gy。 结果 治疗前后患者下肢步行能力明显改善，疼痛明显缓解，1、2年局控率、生存率分别为60.7%、46.4%和53.5%、 35.7%，中位生存期14月，毒性反应主要表现为骨髓抑制、消化道反应及脱发。 结论 DP方案全身化疗并同步放疗治疗NSCLC并脊髓压迫症的患者，有较好的疗效，改善了患者的生存质量，毒性反应可耐受。

Clinical Observation of Concurrent Chemoradiotherapy in Treating Lung Cancer Compli cared Vertebral Metastasis of 30 Cases

Objective To explore the clinical efficacy and adverse reaction of concurrent chemoradiotherapy on lung cancer complicated vertebral metastasis. Methods Thirty cases of NSCLC complicated vertebral metastasis，ECOG remark 0~2 score，underwent DP（Docetaxel 75mg/m²+DDP 75mg/m²，iv drip，d1）regimen chemotherapy， concurrent vertebras external irradiation，applied conventional radiotherapy， 2Gy/fraction/day，5 fractions/week，for 4 weeks with total dose 40Gy. Results After the treatment，the motor function of lower extremity was improved and pain relieved，both showed significant differences（P＜ 0.05），local control rate of 1 and 2 year was 60.7%，46.4%，survival rate of 1 and 2 year was 53.5%， 35.7%，median survival time was 14 months，the major toxicity was myelosupression，nausea/vomiting and alopecia. Conclusion DP regimen chemotherapy combined concurrent vertebras radiotherapy in treating spinal cord compression shows good efficacy， improves the quality of life and the toxicity can be tolerated.